Early Versus Delayed Pneumococcal Vaccination in HIV
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine whether people who are HIV-positive respond better to a vaccine for pneumonia-related disease when they are immunized immediately, or when immunization is delayed until the immune system has improved to a certain level. The study will also compare the effectiveness of polysaccharide and heptavalent vaccines.
Condition or disease
Biological: PneumovaxBiological: Prevnar
Phase 1Phase 2
A multicentre, randomized controlled trial using a two factorial design. Eighty patients will be randomly assigned to receive either Pneumovax (or Pneumo23 according to standard use at site) or heptavalent pneumococcal conjugate vaccine (Prevnar) prior to reconstitution of the immune system or will have immunization delayed until their CD4 count is greater than 200 cells/mm3 after the introduction of antiretroviral therapy. Randomization will be stratified by study centre. Variable block sizes will be used to try to prevent study personnel from guessing the next allocation. Random allocation lists will be generated by computer.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Between 18 and 65 years of age
Have a CD4 cell count below 200 cells/mm3
Willing to begin/change antiretroviral therapy
Willing and able to provide informed consent
Pregnant or breastfeeding
Have had previous pneumococcal vaccination
Have had occurrence of pneumococcal infection (brain, blood or lung infections) in past 5 years
Have hypersensitivity to components of either vaccine
Have acute feverish illness at the time of vaccination
Have had splenectomy (removal of the spleen)
Have received treatment with IVIG within the last 6 months